Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.

CH, Chuah; TS, Chow; CP, Hor; JT, Cheng; HB, Ker; HG, Lee; KS, Lee; N, Nordin; TK, Ng; M, Zaid; NZ, Zaidan; Wahab S, Abdul; NA, Adnan; N, Nordin; TY, Tee; SM, Ong; SK, Chidambaram; M, Mustafa

doi:10.1093/cid/ciab962

Public

Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.

Shared by NobleBlocks on Aug 1, 2022 • 12:00 AM UTC

Authors:

Chuah CH

Chow TS

Hor CP

Abstract

<h4>Background</h4>The role of favipiravir in preventing disease progression in coronavirus disease 2019 (COVID-19) remains uncertain. We aimed to determine its effect in preventing disease progression from nonhypoxia to hypoxia among high-risk COVID-19 patients.<h4>Methods</h4>This was an open-labe...

Subject

Mortality

Disease Progression

Favipiravir

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!